Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NORA DANIEL

Allopathic & Osteopathic Physicians Pediatrics

NPI
1720183106
CMS profile
32608
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$114.62

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $114.62 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI-AVENTIS U.S. LLC $114.62 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NORA DANIEL

NPI 1720183106 · CMS profile ID 32608

Allopathic & Osteopathic Physicians / Pediatrics

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NORA DANIEL, NPI 1720183106, CMS profile ID 32608. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). NORA DANIEL, NPI 1720183106, CMS profile ID 32608. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
NORA DANIEL, NPI 1720183106, CMS profile ID 32608, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1720183106?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $114.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI-AVENTIS U.S. LLC $114.6204/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139598723 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $17.80 1
PY2022 $140.81 2
PY2023 $1,353.47 10
PY2024 $114.62 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,328,285.04 535
PY2024 Principal investigator $517,981.68 120
PY2023 Principal investigator $685,808.52 880
PY2022 Principal investigator $908,256.60 1,978

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

880 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $194.00 12/31/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 998413063
Principal investigator 1 Genentech, Inc. $1,569.00 12/29/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040366719
Principal investigator 1 Genentech, Inc. $23,535.00 12/20/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040366707
Principal investigator 1 Genentech, Inc. $2,736.00 12/20/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040366731
Principal investigator 1 Genentech, Inc. $95,709.00 12/06/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040366695
Principal investigator 1 Genentech, Inc. $15,690.00 11/24/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040366669
Principal investigator 1 Genentech, Inc. $36,087.00 11/20/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040366681
Principal investigator 1 Genentech, Inc. $108,261.00 11/13/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040366657
Principal investigator 1 Genentech, Inc. $265,161.00 10/31/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1040366645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,133.00 08/01/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977173636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977139981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977139991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140195
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140205
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977140993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141144
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977141995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142350
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142496
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977142995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977143997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977144991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145367
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977145997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977146991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977147993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148191
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148201
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977148995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977149009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977149019
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977149029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $140.20 06/14/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 977149037
Principal investigator 1 Chiesi USA, Inc. $320.32 06/02/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595723
Principal investigator 1 Chiesi USA, Inc. $1,500.00 06/01/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595587
Principal investigator 1 Chiesi USA, Inc. $4,000.00 06/01/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051595589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,500.00 05/03/2023 Non-covered Recipient Entity
LINKS CLINICAL TRIALS LLC
A Master Protocol of Randomized, Double-Blind, Placebo-Controlled, Phase 2 Studies of siRNA Gene Silencing for the Treatment of Non- Alcoholic Steatohepatitis (NASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 977106257